CONTEXT: Several observational studies and meta-analyses have reported increased mortality of @entity1 taking @entity5736 and insulin. The impact of @entity1 profiles and concomitant therapies often remains unclear. OBJECTIVE: The objective of the study was to quantify survival of @entity1 after starting @entity413 -lowering agents (GLAs) and compare it with control subjects, matched for risk profiles and concomitant therapies. DESIGN: This was a retrospective, controlled, cohort study. SETTING: The study is based on health expenditure records of the largest Belgian health mutual insurer, covering more than 4.4 million @entity1 . @entity1 : A total of 115 896 @entity1 starting @entity2449 , @entity5736 , or insulin (alone or in combination) between January 2003 and December 2007 participated in the study. Control subjects without @entity10153 therapy were matched for age, gender, history of cardiovascular events, and therapy with antihypertensives, @entity6817 and blood platelet aggregation inhibitors. INTERVENTION(S): There were no interventions. MAIN OUTCOME MEASURE: Five-year survival after the start of @entity10153 was measured. RESULTS: Profiles of @entity1 using different GLAs varied, with @entity1 on @entity5736 being oldest and @entity1 on insulin having more frequently a history of @entity65 . Excess mortality differed across @entity10153 therapies compared with matched controls without GLAs, even after adjusting for observable characteristics. Only @entity2449 monotherapy was not associated with an increased 5-year mortality compared with matched controls, whereas individuals on a combination of @entity5736 and insulin had the highest mortality risks. Age and concomitant use of statins strongly affect survival. CONCLUSIONS: Differences exist in 5-year survival of @entity1 on @entity10153 , at least partly driven by the risk profile of the individuals themselves. @entity2449 use was associated with lowest 5-year mortality risk and statins dramatically lowered 5-year mortality throughout all cohorts.

Mortality in Individuals Treated With XXXX -Lowering Agents: A Large, Controlled Cohort Study.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS', 'people'] @entity6817 :: ('D019821', 'Chemical') :: ['statins'] @entity5736 :: ('D013453', 'Chemical') :: ['sulfonylurea'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose'] @entity10153 :: ('2717', 'Gene') :: ['GLA'] @entity2449 :: ('MESH:D008687', 'Chemical') :: ['Metformin', 'metformin']
@entity413 :: (MESH:D005947,Chemical) :: ['Glucose']
